Current Report Filing (8-k)
January 05 2018 - 4:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): December 29, 2017
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
11682 El Camino Real, Suite 300
San Diego, CA
|
|
|
|
92130
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (858) 997-2400
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 1.01
|
Entry into a Material Definitive Agreement
|
On
December 29, 2017, Adamis Pharmaceuticals Corporation (the “Company”) entered into a First Amendment to Lease (the
“Amendment”), with Pacific North Court Holdings, L.P., a California limited partnership, or Lessor. The Amendment amends
the Office Lease Agreement dated as of April 1, 2014, by and between the Company and Lessor (the “Lease”). Pursuant
to the Lease, the Company rents approximately 7,525 square feet of office space at 11682 El Camino Real, Suite 300, San Diego,
California 92130, which serves as the Company’s corporate headquarters.
Pursuant
to the Amendment, the Company and Lessor have agreed to extend the Term of the Lease through November 30, 2023. The Amendment provides
that the Company shall pay its current base rent through November 30, 2018. Commencing on December 1, 2018 base rent will initially
be $28,219 per month for the first 12 months and will increase annually to $31,760 for the 12 months ending November 30, 2023.
The Amendment also provides for one option to expand whereby the Company has a right of first refusal for an additional 3,457 square
feet of certain office space within the property.
The
foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment,
a copy of which is filed herewith as an Exhibit and incorporated herein by reference.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
Dated: January 5, 2018
|
By:
|
/s/ Robert O. Hopkins
|
|
Name:
Title:
|
Robert O. Hopkins
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024